Four circadian rhythm-related genes predict incidence and prognosis in hepatocellular carcinoma

Zhenyu Wu*, Hao Hu†, Qiang Zhang, Tengfei Wang, Huixing Li, Yungang Qin, Xiangnan Ai, Wen Yi, Xiaojun Wei, Wei Gao and Caiguo Ouyang

Department of Hepatobiliary Surgery, Aerospace Center Hospital, Beijing, China

Circadian dysregulation can be involved in the development of malignant tumors, though its relationship with the progression of hepatocellular carcinoma is not yet fully understood. We identified genes related to circadian rhythms from the Cancer Genome Atlas (TCGA), measured gene expression, and conducted genomic difference analysis to construct a circadian rhythm-related signature. The resulting prognosis model proved to be an effective biomarker, as demonstrated by Kaplan-Meier survival analysis for both the training (n = 370, P = 2.687e-10) and external validation cohorts (n = 230, P = 1.45e-02). Further, we found that patients considered ‘high risk’, with an associated poor prognosis, displayed elevated levels of immune checkpoint genes and immune infiltration. We also conducted functional enrichment, which indicated that the risk model showed a significant positive correlation with certain malignant phenotypes, including G2M checkpoint, MYC targets, and the MTORC1 signaling pathway. In summary, we identified a novel circadian rhythm-related signature allowing assessment of prognosis for hepatocellular carcinoma patients, and further can be used to predict immune infiltration sensitivity.

KEYWORDS
liver cancer, Circadian clock, overall survival, gene signature, immune

Introduction

Hepatocellular carcinoma, the most common form of liver cancer, is one of the most common causes of cancer-related deaths worldwide, and is associated with substantial costs (1). Potential treatments at early stages include liver resection, ablation, and transplantation, though most HCC patients are diagnosed at later stages, limiting treatment options (2). Treatments for advanced-stage HCC are primarily systemic therapy approaches, including immune checkpoint inhibitors and targeted agents (3).
Despite these available treatments, HCC patients generally experience recurrence and chemoresistance, resulting in overall poor prognosis. Empowered by innovations in multi-omics profiling, contemporary studies have provided prognostic candidates with clinical applications. In order to further the field, it is critical to identify strong molecular biomarkers that correlate with outcomes for HCC patients (4).

The molecular circadian clock is an evolutionarily conserved system that coordinates internal time with the external environment. The circadian clock is integral in homeostasis and regulation, and manages many biological activities and behaviors (5, 6). Within the hypothalamus, the suprachiasmatic nucleus (SCN) has a central clock that regulates daily rhythms through neural and humoral coordination of additional clocks found in peripheral tissues and organs, and these clocks control physiological functions including sleep/wake cycles and hormone secretion. The World Health Organization lists circadian clock disruption as a putative carcinogen, as evidenced by population and laboratory-based findings (7, 8). Thus, research into the relationship between the expression of circadian-related genes and tumor development has been a focus. A previous study demonstrated that circadian-related genes are correlated with the incidence and progression of NSCLC (9). Further research is required to fully explore the relationship between circadian genes and the prognosis for LIHC patients (10).

In the current study, we investigate the predictive role of circadian genes in LIHC patients using The Cancer Genome Atlas (TCGA) data from the NCI Genomic Data Commons, including clinical characteristics and the SNV, CNV, methylation, and mRNA expression profiles of tumor and tumor-adjacent normal tissues. We use these data to establish a prognostic multigene signature with differentially expressed circadian clock genes and validate this signature with the ICGC dataset. Essential molecular mechanisms are explored by gene set enrichment analysis (GSEA) using Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways (10).

### Materials and methods

#### Data collection and processing

Multi-omics data profiles for the 14 circadian genes (10–13) from 374 HCC patients together with their clinical data were obtained from TCGA LIHC datasets (https://cancergenome.nih.gov/). Heatmap was completed to visualize expression levels of the 14 circadian genes in HCC and of the normal tissues in the TCGA LIHC cohort. RNA-seq data of 232 HCC cases were also obtained from the ICGC cohort (https://dcc.icgc.org/projects/LIRI-JP). Clinical data for the TCGA and ICGC cohorts are displayed in Table 1. Transcriptome RNA sequencing data in the count and FPKM format and corresponding clinical data were acquired from TCGA (https://portal.gdc.cancer.gov/) and used as the training dataset. Genes with average expression < 0.5 were omitted from the current study. The EdgeR package in R was applied for genomic difference detection with |logFC| > 1 and adjusted P < 0.05 filtering. Volcano plot was created with the ggplot2 package to visualize the difference analysis.

#### Survival analysis

The survival package in R was used for Kaplan-Meier survival analysis with log-rank test, and for univariate and multivariate Cox regression. The glmnet R package was used for Lasso, and 10-fold cross-validation was implemented. Calibration plots were created with the rms package. The survivalROC package was used to create the time-dependent ROC curves.

Univariate Cox regression test was implemented to evaluate the correlation of circadian-related genes with clinical outcomes for HCC patients. Circadian-related genes with P<0.05 were included in further analysis with the Univariate Cox regression test with the least absolute shrinkage and selection operator (LASSO) algorithm with the "glmnet" package in R. A 4 gene predictive signature was screened using the minimum criteria.

### Table 1. Demographical and clinical characteristics.

| level        | ICGC_LIRI | TCGA_LIHC | p     |
|--------------|-----------|-----------|-------|
| n            | 228       | 370       |       |
| gender       |           |           |       |
| female       | 59 (25.9) | 121 (32.7)| 0.094 |
| male         | 169 (74.1)| 249 (67.3)|       |
| age_at_index | 67.18 (10.17) | 59.42 (13.53) | <0.001 |
| stage        | 1         | 1         |       |
| 1            | 35 (15.4) | 170 (49.1)| <0.001|
| 2            | 104 (45.6)| 86 (24.9) |       |
| 3            | 70 (30.7) | 85 (24.6) |       |
| 4            | 19 (8.3)  | 5 (1.4)   |       |
| time         | 814.74 (417.21) | 802.91 (726.97) | 0.823 |
| status       | 0         | 1         |       |
| 0            | 186 (81.6)| 240 (64.9)| <0.001|
| 1            | 42 (18.4)| 130 (35.1)|       |
Risk score for each patient was computed using the normalized expression level of each gene as well as its coefficients. The formula was the following: coefficient (gene i) derived from the Cox proportional hazards regression analysis.

The TCGA LIHC cohort was split into two sub-groups on the basis of the median value of the risk score.

GSEA and GSVA

Gene ontology (GO) was employed to investigate potential functions based on the differential gene profiles of the two groups ([log2FC] ≥ 1, FDR <0.05). The hallmark gene sets v. 7.4 were obtained from MSigDB and used as the reference dataset. GSVA was carried out with the GSVA package of R, and parameters were the following: min. size = 10, max. size =500, verbose = Ture, and parallel. size = 1. Difference detection was conducted with Limma, with the filtering threshold |logFC| > 0.1 and adjusted P < 0.05. GSEA was conducted with GSEA software (version 4.1.0), with the number of permutations as 1000 (14). The gene sets with nominal P < 0.05 and FDR q <0.05 were considered statistically significant. An interaction network of 14 circadian-related genes was recapitulated with STRING (http://string-db.org).

Chemotherapeutic effectiveness analyses

The oncoPredict R package was used to assess the chemotherapeutic sensitivity of LIHC patients in the TCGA-LIHC cohort (15). Transcriptome data and IC50 values of 20 different cell lines were obtained from the GDSC database (https://www.cancerrxgene.org/) in order to corroborate the predictive value of CRRS for response to chemotherapy. Microarray RNA expression data retrieved from the GDSC dataset was normalized using Robust Multi-Array Average (RMA).

Statistical analysis

R software (version 4.1.0) was used for statistical analysis. The Wilcoxon Signed-rank test was used for continuous variables from the bioinformatical analyses. Violin diagrams and boxplots were both created with the ggplot2 package. Chi-square test was employed for categorical variables, and results were visualized using the ggplot2 package.

Results

Expression profile of circadian clock genes and clinical features in TCGA LIHC cohort

We included circadian clock genes (CCGs), including both core clock genes and clock control genes that were found in previous studies in our analysis (11, 16). SNVs and CNVs related to CCGs were investigated. Samples with mutated or CNVs CSNK1D, PER2, NR1D1, CUL1, and BTRC accounted for 1% of all samples from the TCGA dataset (Figure 1A). Additionally, the CNV profile of core CCGs could explain the abnormal expression of the CCGs. Expression of CSNK1D was increased in tumor CNV amplification samples relative to nonapplication samples and normal tissues, which corresponds with the CNV profile of the CCGs. The expression levels of CUL1, NR1D1, and PER2 were lower in tumor deletion samples than in other tumor and normal tissue samples (Figure 1B). Methylation and expression profiles of the CCGs between normal liver tissue and hepatocellular carcinoma samples is shown in the heatmap (Figures 1C, D). High methylation was observed for CLU1, PER3, PER3, RORA, and PER1, but was not associated with RNA expression; these genes showed high expression in the LIHC datasets. Low expression was observed for FBXL21 and RORB, but the methylation levels were not elevated. For FBXL21, only the partial methylation site was elevated. No significant relationship was observed between the methylation and gene expression of CCGs in LIHC.

Construction of the circadian gene based signature in the TCGA LIHC cohort

To investigate the predictive value of these differentially expressed CCGs, we first carried out univariate analysis of the standardized expression of the CCGs from the LIHC datasets in the training sets to detect prognostic CCGs. In the TCGA LIHC cohort, 9 circadian genes were differentially expressed between tumor and tumor-adjacent normal tissues. Three candidate genes were significantly associated with OS, as detected by univariate Cox proportional regression analysis (Figure 2A). In addition, we performed LASSO Cox proportional hazard regression to screen the ultimate CCGs for the risk-score models, and found that expression of 4 CCGs correlated with OS in LIHC patients (Figure 2B). Therefore, we constructed a risk-score model for predicting the prognosis of LIHC patients using the calculation formula described in the Methods. We identified PER1, CRY2, CSNK1D, and FBXL21 as risk genes in the LIHC risk-score model (Figure 2C). Survival analysis revealed that there was a significant difference between the high-risk group and the low-risk group for OS, and being in the high-risk group significantly correlated with an poorer prognosis (LIHC: p < 0.0001) (Figure 2D).

Validating the signature in the ICGC cohort

We confirmed the accuracy and stability of the prognostic risk-score model using the testing sets, which included the LIRI-
JP cohorts obtained from ICGC. OS was used as the indicator for comparison of the groups, and samples were split into low and high risk-score groups according to the calculated risk score. The formula was as described in the Methods. For the testing set of the LIRI type, 230 samples were separated into low and high risk-score groups. Survival analysis showed that there was a significant difference between the high and low risk-score groups (p < 0.0001, HR: 1.493, 95% CI: 1.248 to 1.787) (Figure 3A). To summarize, our results confirmed that the risk-score model based on CCGs signature was stable and accurate in predicting the prognosis of patients (Figures 3B–F).

Identification of the circadian-based signature as an independent prognostic factor for HCC

We then investigated the accuracy and stability of the risk score for use as a clinical indicator. We analyzed seven variables, including age, gender, tumor stage, and risk-score using the TCGA LIHC and ICGC LIRI groups, with multivariate analysis and Cox proportional hazard regression, respectively (Figures 4C, D). Our analysis showed that risk-score was an independent prognostic indicator in both LIHC and LIRI patients. We then constructed ROC curves for the different variables to evaluate the risk-score as classifiers, and the AUC was calculated and used as the basis for evaluation (LIHC: AUC 0.71; LUSC: AUC 0.76) (Figures 4E, F). Our results indicated that the risk-score showed accuracy and predictability for comparing other clinical characteristics in liver cancer samples. The protein expression level of these genes in liver hepatocellular carcinoma samples was also detected via immunohistochemistry (IHC), as shown in Supplementary Figure 1.

Functions and pathways correlated with the circadian gene-based signature

In the TCGA dataset, genes that were differentially expressed in the high-risk and low-risk groups were subjected to GSEA to
evaluate the hallmark, KEGG, and GO pathways (Figure 4). The results indicated that tumorigenesis pathways related to G2M checkpoint, E2F target, MYC target, mitotic spindle, and mTORC1 signal were enriched in the high-risk group, while metabolism pathways related to xenobiotic, fatty acid, bile acid, adipogenesis, coagulation, oxidative phosphorylation, and peroxisome were enriched in the low-risk group. (Figure 4B).

In the TCGA dataset, KEGG enrichment analysis based on GSEA analysis (Figure 4C) suggested that CCGs modulate the cAMP signaling pathway, Epstein–Barr virus infection, human papillomavirus infection, neuroactive ligand–receptor interaction, spinocerebellar ataxia, and viral carcinogenesis. Additionally, GO analysis based on GSEA analysis (Figure 4D) suggested that CCGs modulate carbohydrate-binding, leukocyte apoptotic process, lipoprotein metabolic process, modulation of the process of another organism, response to acid chemical, response to heat, and response to nutrient, and the differential expression of genes between the high-risk and low-risk groups also supported that conclusion.

To identify the key player in LIHC, we developed the gene coexpression network in the TCGA-LIHC and ICGC-LIRI datasets. We investigated the correlation between risk score-related CCGs and gene modules. The heatmap revealed the correlations between the modules and risk score genes in the TCGA-LIHC and ICGC-LIRI datasets. We found that CRY2 was negatively correlated with MYOGENESIS and GLYCOLYSIS, while others were positively correlated. Additionally, CRY2 and PER1 were negatively correlated with MITOTIC_SPINDLE and G2M_CHECKPOINT, while CSNK1D and FBXL21 were positively correlated (Figures 5C, D).

**Drug response and signature pathway profile based on risk score group**

We also predicted drug sensitivity according to riskScore. Entospletinib, KU55933, PF4708671, Ribociclib, and WZ4003 showed a positive correlation with risk score, indicating their potential role as drugs targeting liver hepatocellular carcinoma, both in TCGA-LIHC and ICGC-LIRI datasets. We next assessed the association between risk score and signature pathway in the TCGA dataset. We used the ssGSEA algorithm, and found that higher risk score correlated with a higher arachidonic acid.
metabolism, cardiolipin biosynthesis, Hexosamine Biosynthesis, and m6A molecular cancer genesets, while lower risk score was associated with higher Valine Leucine and Isoleucine Biosynthesis (Figure 6C). These findings were validated in the other datasets (Figure 6D) supporting a difference in metabolism between the high-risk and low-risk samples.

Discussion

Liver cancer diagnosis rates have tripled in the past three decades, and mortality has also increased (17). Thus, is it critical to identify effective biomarkers that allow creation of accurate predictive models for HCC patient OS. Ongoing investigation of
metabolomics has revealed the role of metabolism in the incidence and development of cancer (18).

The circadian clock affects and drives many biological processes, and disruption to the circadian clock is implicated in breast and colorectal cancers (19, 20), with dysregulation of CCGs correlated with cancer progression (21, 22). In the current study, we established a predictive model and demonstrated that a dysregulated circadian clock correlated with hepatocellular carcinoma. The risk score model incorporating the four genes CRY2, CSNK1D, FBXL21, and PER1, based on the TCGA-LIHC dataset, was shown to be robust. These four genes have been demonstrated in previous studies to be associated with tumor development and cancer metastasis (23–26). CRY2 codes for a flavin adenine dinucleotide-binding protein that acts as a regulator of the circadian clock, and may promote growth of tumor cells (26). CSNK1D encodes an enzyme that has many roles, including in circadian rhythm, response to DNA damage, the cell cycle, functions of the cytoskeleton, and others (27, 28). FBXL21 is a gene that plays a role in circadian clock oscillation by mediating ubiquitination and stabilization of cryptochromes (29). PER1 is important in the maintenance of the circadian rhythm in cells, and its down-regulation can enhance tumor growth (25). Based on these genes, the current study showed that patients with a high-risk score had significantly reduced OS. Our predictive model was robust and accurate in correlating clinicopathological data and outcomes with higher risk scores.

We used GSEA analysis to examine the biological mechanisms driving outcomes for the two patient groups. We found that the top-upregulated HALLMARK gene sets in patients in the high-risk group were primarily associated with cell cycle-related pathways, which form the canonical signaling pathways involved in the initiation, invasion, and metastasis of tumor cells. In addition to the three common signal pathways “DNA-Repair,” “Myc-Targets-V1,” and “Myc-Targets-V2,” two other significantly enriched immune-related pathways were identified in patients in the low-risk group. The mechanistic target of the rapamycin (mTOR) signaling pathway is closely related to immune and inflammatory effects and plays an important role in activation and differentiation.

We also that predicted Entospletinib, KU−55933, PF−4708671, Ribociclib, and WZ4003 may be potential drugs for high-risk LIHC patients. Notably, a previous study supported Entospletinib monotherapy in patients with relapsed or refractory chronic lymphocytic leukemia previously treated with B-cell receptor
inhibitors: the results of a phase 2 study (30) showed that Ribociclib was cytotoxic and reduced cell proliferation rate. The effect on cell viability was enhanced when Ribociclib was combined with progesterone and/or mitotane (31). Therefore, the risk score model can also be applied to predict potential drugs for treatment of LIHC. Collectively, these results indicate the accuracy and potential wide application of our model based on 4 genes for assessing the association between circadian dysregulation and cancer incidence.

There are several limitations to this study. It is a bioinformatic study without sample verification or in vitro and in vivo experiments. Moreover, the current study only focuses on gene transcription regulation. Other regulatory layers such as epigenetic, post-transcription, translation efficiency, and post-translation modification also affect the chronophysiology and pathology (32). Future investigations on experiments and prospective trials are needed to assess the predictive score of gene signature and its mechanisms.

**Conclusion**

This study examined the potential role of the expression of circadian-related genes in the development of HCC. We found that 4 genes could be used to accurately predict the OS for HCC patients in the TCGA LIHC and ICGC (LIRI-JP) cohorts.
FIGURE 6
Comparison of drug response and signature score between high-risk and low-risk groups. (A, B) Drug response of the TCGA (A) and ICGC (B) datasets. (C, D) Signature scores of TCGA (C) and ICGC (D).
Further, we identified one of the four genes, CRY2, as a possible molecular target for HCC incidence and progression. These findings provide a theoretical basis for ongoing study of circadian-related genes for predicting and treating HCC.

Data availability statement

The original contributions presented in the study are included in the article/Supplementary Material. Further inquiries can be directed to the corresponding author.

Author contributions

ZW and HH designed the study. HH, QZ, and TW performed the experiments. HH, HL, QG, XA, XW, WY, and WG analyzed the data. ZW, HH, and CO wrote the manuscript.

Funding

The authors would like to thank ICGC (https://www.icgc-arg.org) and TCGA (http://cancergenome.nih.gov) for data collection, cBioPortal (http://www.cbioportal.org, version v3.2.11) for the provision of data processing and customizable functions.

References

1. Villanueva A. Hepatocellular carcinoma. N Engl J Med (2019) 380:1450–62. doi: 10.1056/NEJMra1713263
2. Yang JD, Hainaut P, Gores GJ, Amadou A, Plymouth A, Roberts LR. A global view of hepatocellular carcinoma: Trends, risk, prevention and management. Nat Rev Gastroenterol Hepatol (2019) 16:589–604. doi: 10.1038/s41575-019-0186-v
3. Huang A, Yang XR, Chung WY, Dennison AR, Zhou J. Targeted therapy for hepatocellular carcinoma. Signal Transduct Target Ther (2020) 5:146. doi: 10.1038/s41392-020-00264-x
4. Ni W, Buan S, Zhu M, Song Q, Zhang J, Xiao M, et al. Identification and validation of ubiquitin-specific proteases as a novel prognostic signature for hepatocellular carcinoma. Front Oncol (2021) 11:629327. doi: 10.3389/fonc.2021.629327
5. Fu L, Rettnier NM. The circadian clock in cancer development and therapy. Prog Mol Biol Transl Sci (2013) 119:221–82. doi: 10.1016/B978-0-12-396971-2.00009-9
6. Panda S, Antoch MP, Miller BH, Su AI, Schook AB, Straume M, et al. Coordinated transcription of key pathways in the mouse by the circadian clock. Cell (2002) 109:307–20. doi: 10.1016/S0092-8674(02)00722-5
7. Lunn BM, Blask DE, Coogan AN, Figueiro MG, Gorman MR, Hall JE, et al. Health consequences of electric lighting practices in the modern world: A report on the national toxicology program’s workshop on shift work at night, artificial light at night, and circadian disruption. Sci Total Environ (2017) 607–608:1073–84. doi: 10.1016/j.scitotenv.2017.07.056
8. Straif K, Baan R, Grosse Y, Secretan B, El Ghissassi F, Bouvard V, et al. Carcinogenicity of shift-work, painting, and fire-fighting. Lancet Oncol (2007) 8:1065–6. doi: 10.1016/S1470-2045(07)70373-X
9. Qiu M, Chen YB, Jin S, Fang XF, He XX, Xiong ZF, et al. Research on circadian clock genes in non-small-cell lung carcinoma. Chronobiol Int (2019) 36:739–50. doi: 10.1080/07420528.2018.1509080
10. Gao X, Tang M, Tian S, Li J, Liu W. Identification of a circadian gene signature that predicts overall survival in lung adenocarcinoma. PeerJ (2021) 9:e17133. doi: 10.7717/peerj.11733
11. Cox KH, Takahashi JS. Circadian clock genes and the transcriptional architecture of the clock mechanism. J Mol Endocrinol (2019) 63(4):R83–r102. doi: 10.1530/JME-19-0153
12. Li M, Chen Z, Jiang T, Yang X, Du Y, Liang J, et al. Circadian rhythm-associated clinical relevance and tumor microenvironment of non-small cell lung cancer. J Cancer (2021) 12:2582–97. doi: 10.7150/jca.52454
13. Wang Z, Su G, Dai Z, Meng M, Zhang H, Fan F, et al. Circadian clock genes promote glioma progression by affecting tumour immune infiltration and tumour cell proliferation. Cell Prolif (2021) 54:e12988. doi: 10.1111/cip.12988
14. Zeng D, Ye Z, Shen R, Yu G, Wu J, Xiong Y, et al. 10BR: Multi-omics immuno-oncology biological research to decode tumor microenvironment and signatures. Front Immunol (2021) 12:687975. doi: 10.3389/fimmu.2021.687975
15. Maeser D, Graeber RE, Huang RS. oncoPredict: An r package for predicting in vivo or cancer patient drug response and biomarkers from cell line screening data. Briefings Bioinf (2021) 22(6):bbab260. doi: 10.1093/bib/bbab260
16. Uki H, Ueda HR. Systems biology of mammalian circadian clocks. Annu Rev Physiol (2010) 72:579–603. doi: 10.1146/annurev-physiol-073109-130051
17. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA: Cancer J Clin (2020) 70:7–30. doi: 10.3322/caac.21590
18. Lin X, Wu Z, Hu H, Luo ML, Song E. Non-coding RNAs rewire cancer metabolism networks. Semin Cancer Biol (2021) 75:116–26. doi: 10.1016/j.semcancer.2020.12.019
19. Papagiannakopoulos T, Bauer MR, Davidson SM, Heinmann M, Subbaraj L, Bhutkar A, et al. Circadian rhythm disruption promotes lung tumorigenesis. Cell Metab (2016) 24:324–31. doi: 10.1016/j.cmet.2016.07.001

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Supplementary material

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fonc.2022.937403/full#supplementary-material
20. Samuelsson LB, Bovbjerg DH, Roecklein KA, Hall MH. Sleep and circadian disruption and incident breast cancer risk: An evidence-based and theoretical review. *Neurosci Biobehav Rev* (2018) 84:35–48. doi: 10.1016/j.neubiorev.2017.10.011

21. Li A, Lin X, Tan X, Yin B, Han W, Zhao J, et al. Circadian gene clock contributes to cell proliferation and migration of glioma and is directly regulated by tumor-suppressive miR-124. *FEBS Lett* (2013) 587:2455–60. doi: 10.1016/j.febslet.2013.06.018

22. Chen Z, Liu P, Li C, Luo Y, Chen I, Liang W, et al. Deregulated expression of the clock genes in gliomas. *Technol Cancer Res Treat* (2013) 12:91–7. doi: 10.7785/tcrt.2012.500250

23. Chen AB, Parico GCG, Fribourgh JL, Ibrahim LH, Bollong MJ, Partch CL, et al. CRY2 missense mutations suppress P53 and enhance cell growth. *Proc Natl Acad Sci USA* (2021) 118(27). doi: 10.1073/pnas.2101416118

24. Xu P, Ianes C, Gartner F, Liu C, Burster T, Bakulev V, et al. Structure, regulation, and (patho-)physiological functions of the stress-induced protein kinase CK1 delta (CSNK1D). *Gene* (2019) 715:144005. doi: 10.1016/j.gene.2019.144005

25. Liu Y, Hao J, Yuan G, Wei M, Bu Y, Jin T, et al. PER1 as a tumor suppressor attenuated in the malignant phenotypes of breast cancer cells. *Int J Gen Med* (2021) 14:7077–87. doi: 10.2147/IJGM.S328184

26. Liu L, Shen H, Wang Y. CRY2 is suppressed by FOXM1 mediated promoter hypermethylation in breast cancer. *Biochem Biophys Res Commun* (2017) 490:44–50. doi: 10.1016/j.bbrc.2017.06.003

27. Fish KJ, Cegieda A, Getman ME, Landes GM, Virshup DM. Isolation and characterization of human casein kinase 1 epsilon (CK1), a novel member of the CK1 gene family. *J Biol Chem* (1995) 270:14875–83. doi: 10.1074/jbc.270.25.14875

28. Zhang H, Qiu C, Zeng H, Zhu W, Lyu W, Luo X. Upregulation of stress-induced protein kinase CK1 delta is associated with a poor prognosis for patients with hepatocellular carcinoma. *Genet Test Mol Biomarkers* (2021) 25:504–14. doi: 10.1089/gtmb.2020.0093

29. Hirano A, Yumimoto K, Tsunematsu R, Matsumoto M, Oyama M, Kozaka-Hata H, et al. FBXL21 regulates oscillation of the circadian clock through ubiquitination and stabilization of cryptochromes. *Cell* (2013) 152:1106–18. doi: 10.1016/j.cell.2013.01.054

30. Awan FT, Thirman MJ, Patel-Donnelly D, Assouline S, Rao AV, Ye W, et al. Entospletinib monotherapy in patients with relapsed or refractory chronic lymphocytic leukemia previously treated with b-cell receptor inhibitors: Results of a phase 2 study. *Leuk Lymphoma* (2019) 60:1972–7. doi: 10.1080/10428194.2018.1562180

31. Abate A, Rossini E, Tamburello M, Lagana M, Cosentini D, Grisanti S, et al. Ribociclib cytotoxicity alone or combined with progesterone and/or mitotane in in vitro adrenocortical carcinoma cells. *Endocrinology* (2022) 163. doi: 10.1210/endcr/bqab248

32. Jiang C, Liu P, La CM, Guan D. In silico integrative analysis of multi-omics reveals regulatory layers for diurnal gene expression in mouse liver. *Front Endocrinol (Lausanne)* (2022) 13:955070. doi: 10.3389/fendo.2022.955070